Risks and Benefits for Sirolimus in Aging Prevention.

Abstract

There is keen interest amongst the general population in preventing aging and age-related infirmities. Sirolimus is approved for preventing organ rejection in kidney transplant patients, has immune-modulating and growth-inhibitory properties, and is one of the therapies currently being used off-label for this purpose. There is a lack of formal guidance, such as a policy statement or position paper, on the appropriate dosing and administration of sirolimus for aging prevention. The American College of Clinical Pharmacology strongly recommends that clinicians prescribing sirolimus weigh the benefits and risks of sirolimus for off-label use in aging prevention, ensuring patients understand that such prescriptions lack any regulatory approval and rigorous supporting evidence. Health care providers are also encouraged to inform patients of the available clinical evidence and ongoing clinical trials in age-related conditions to build a stronger foundation of safety, efficacy, and optimal dosing for sirolimus in aging prevention.